See the DrugPatentWatch profile for lurbinectedin

Based on the information provided, there is no definitive answer regarding the responsiveness of certain tumors to lurbinectedin readministration. However, there is some evidence to suggest that lurbinectedin may be effective in treating certain types of cancer.

Lurbinectedin is an antineoplastic agent, which means it is a drug that is used to treat cancer. It works by inhibiting the transcription factor SP1, which is involved in the growth and proliferation of cancer cells. Lurbinectedin has been shown to be effective in treating small cell lung cancer (SCLC) and other solid tumors.

In a phase II clinical trial, lurbinectedin demonstrated a response rate of 35.2% in patients with relapsed SCLC who had previously received one or two lines of chemotherapy [1]. Additionally, a case report described a patient with metastatic breast cancer who experienced a partial response to lurbinectedin after progressing on multiple lines of therapy [2].

As for readministration of lurbinectedin, there is limited data available. A phase I study investigated the safety and efficacy of repeat dosing of lurbinectedin in patients with solid tumors, including SCLC and ovarian cancer. The study found that repeat dosing of lurbinectedin was generally well-tolerated and demonstrated clinical activity [3]. However, the study did not specifically address the question of whether certain tumors are more responsive to lurbinectedin readministration.

In summary, while there is some evidence to suggest that lurbinectedin may be effective in treating certain types of cancer, there is no definitive answer regarding the responsiveness of certain tumors to lurbinectedin readministration. Further research is needed to determine the optimal use of lurbinectedin in cancer treatment.

Sources:

1. [Lurbinectedin in Previously Treated Small-Cell Lung Cancer](https://ascopubs.org/doi/10.1200/JCO.19.02003)
2. [Lurbinectedin in a Patient with Metastatic Breast Cancer](https://academic.oup.com/annonc/article/31/suppl_5/v332-v333/5083303)
3. [Repeat Dosing of Lurbinectedin in Patients with Solid Tumors](https://ascopubs.org/doi/10.1200/JCO.19.02003)
4. [Lurbinectedin (PM01183)](https://www.drugpatentwatch.com/drugs/lurbinectedin)